The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | BCMA/CD38 CAR-T for R/R MM: promising trial results
Heng Mei, MD, Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China, discusses the first-in-human clinical trial (ChiCTR1800018143) of a bispecific CAR T-cell therapy targeting BCMA and CD38 in patients with relapsed/refractory (R/R) multiple myeloma (MM). Dr Mei highlights the promising results of the trial, in particular improved efficacy and manageable toxicities. The initial data provide strong evidence to support the further development of the dual-target CAR-T for R/R MM. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
